We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Methods for Brain Atrophy MR Quantification in Multiple Sclerosis: Application to the Multicenter INNI Dataset.
- Authors
Storelli, Loredana; Pagani, Elisabetta; Pantano, Patrizia; Piervincenzi, Claudia; Tedeschi, Gioacchino; Gallo, Antonio; De Stefano, Nicola; Battaglini, Marco; Rocca, Maria A.; Filippi, Massimo
- Abstract
Background: Current therapeutic strategies in multiple sclerosis (MS) target neurodegeneration. However, the integration of atrophy measures into the clinical scenario is still an unmet need. Purpose: To compare methods for whole‐brain and gray matter (GM) atrophy measurements using the Italian Neuroimaging Network Initiative (INNI) dataset. Study Type: Retrospective (data available from INNI). Population: A total of 466 patients with relapsing–remitting MS (mean age = 37.3 ± 10 years, 323 women) and 279 healthy controls (HC; mean age = 38.2 ± 13 years, 164 women). Field Strength/Sequence: A 3.0‐T, T1‐weighted (spin echo and gradient echo without gadolinium injection) and T2‐weighted spin echo scans at baseline and after 1 year (170 MS, 48 HC). Assessment: Structural Image Evaluation using Normalization of Atrophy (SIENA‐X/XL; version 5.0.9), Statistical Parametric Mapping (SPM‐v12); and Jim‐v8 (Xinapse Systems, Colchester, UK) software were applied to all subjects. Statistical Tests: In MS and HC, we evaluated the intraclass correlation coefficient (ICC) among FSL‐SIENA(XL), SPM‐v12, and Jim‐v8 for cross‐sectional whole‐brain and GM tissue volumes and their longitudinal changes, the effect size according to the Cohen's d at baseline and the sample size requirement for whole‐brain and GM atrophy progression at different power levels (lowest = 0.7, 0.05 alpha level). False discovery rate (Benjamini–Hochberg procedure) correction was applied. A P value <0.05 was considered statistically significant. Results: SPM‐v12 and Jim‐v8 showed significant agreement for cross‐sectional whole‐brain (ICC = 0.93 for HC and ICC = 0.84 for MS) and GM volumes (ICC = 0.66 for HC and ICC = 0.90) and longitudinal assessment of GM atrophy (ICC = 0.35 for HC and ICC = 0.59 for MS), while no significant agreement was found in the comparisons between whole‐brain and GM volumes for SIENA‐X/XL and both SPM‐v12 (P = 0.19 and P = 0.29, respectively) and Jim‐v8 (P = 0.21 and P = 0.32, respectively). SPM‐v12 and Jim‐v8 showed the highest effect size for cross‐sectional GM atrophy (Cohen's d = −0.63 and −0.61). Jim‐v8 and SIENA(XL) showed the smallest sample size requirements for whole‐brain (58) and GM atrophy (152), at 0.7 power level. Data Conclusion: The findings obtained in this study should be considered when selecting the appropriate brain atrophy pipeline for MS studies. Evidence Level: 4. Technical Efficacy: Stage 1.
- Subjects
SIENA (Italy); COLCHESTER (England); CEREBRAL atrophy; MULTIPLE sclerosis; FALSE discovery rate; INTRACLASS correlation; GRAY matter (Nerve tissue)
- Publication
Journal of Magnetic Resonance Imaging, 2023, Vol 58, Issue 4, p1221
- ISSN
1053-1807
- Publication type
Article
- DOI
10.1002/jmri.28616